MACROGENICS INC MGNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-12.89
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $149.5M | -$74.6M | — | -$83.0M | $55.6M |
| 2024 | $150.0M | -$67.0M | — | -$72.1M | $116.1M |
| 2023 | $58.7M | -$9.1M | — | -$80.0M | $152.6M |
| 2022 | $151.9M | -$119.8M | — | -$90.6M | $142.0M |
| 2021 | $77.4M | -$202.1M | — | -$150.0M | $239.6M |
| 2020 | $104.9M | -$129.7M | — | -$117.8M | $295.9M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| O'Brien Federica F. | director | 2026-05-18 | Option exercise | 3,750 | — |
| Jackson Scott Thomas | director | 2026-05-18 | Option exercise | 3,750 | — |
| HEIDEN WILLIAM K | director | 2026-05-18 | Option exercise | 3,750 | — |
| SIEGEL JAY PHILIP | director | 2026-05-18 | Option exercise | 3,750 | — |
| Liu Margaret | director | 2026-05-18 | Option exercise | 3,750 | — |
| Chhabra Meenu | director | 2026-05-18 | Option exercise | 3,750 | — |
| HURWITZ EDWARD | director | 2026-05-18 | Option exercise | 3,750 | — |
| STUMP DAVID C | director | 2026-05-18 | Option exercise | 3,750 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.89 (distress)
- Working capital / assets 0.688
- Retained earnings / assets -4.845
- EBIT / assets -0.284
- Equity / liabilities 0.276
Source: SEC EDGAR filings · CIK 0001125345 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.